<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261205</url>
  </required_header>
  <id_info>
    <org_study_id>Local/2017/0M-01</org_study_id>
    <nct_id>NCT04261205</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Tolerance of Plasmapheresis by Double Cascade Filtration in a University Centre</brief_title>
  <acronym>DFPPSURV</acronym>
  <official_title>Evaluation of the Efficacy and Tolerance of Plasmapheresis by Double Cascade Filtration in a University Centre</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study is being carried out to evaluate the biological, technical and clinical/biological
      efficacy of this technique, the practice of which is standardized in the department, in order
      to evaluate our practices and to improve them if necessary. As part of this study, the
      investigators will ask all patients scheduled for this procedure to participate in this
      observational prospective study without changing usual practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to conduct a prospective evaluation of the practice of
      apheresis by Double Filtration System Cascade system in a university centre in current
      practice with evaluation of the technical and biological effectiveness as the main objective
      and clinical and biological tolerance as the secondary objective for all consecutive sessions
      performed in a university centre over a period of 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2018</start_date>
  <completion_date type="Anticipated">August 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Apheresis by DFPP and biological efficiency</measure>
    <time_frame>over a period of one year</time_frame>
    <description>quantification of the purification carried out (volume)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical side effects</measure>
    <time_frame>within 1 hour of all session</time_frame>
    <description>catheter dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological side effects</measure>
    <time_frame>within 1 hour of all session</time_frame>
    <description>Bleeding rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variation of Hb, platelet and albumin before and after session</measure>
    <time_frame>within 1 hour of all session</time_frame>
    <description>% of Hb, platelet and albumin</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Kidney Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 18 years of age who consecutively benefit from plasmapheresis sessions by
        double cascade filtration system during hospitalization at the University Hospital of
        Nîmes, within the framework of the usual indications retained in the department for a
        period of 12 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Over 18 years of age I indication for plasmapheresis and hospitalized at Chu de Nimes.

        Exclusion Criteria:

        Under guardianship or curatorship Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Olivier Moranne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Moranne, MD, PhD</last_name>
    <phone>+33 (0) 4 66 68 32 59</phone>
    <email>olivier.moranne@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Clarisse SIMONET, PhD</last_name>
    <phone>+33(0) 4 66 68 36 78</phone>
    <email>anne.clarisse.simonet@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nîmes, Hôpital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

